• Appointment of Dr. Steven Levin of Johns Hopkins University to Endonovo’s scientific advisory board is expected to help facilitate the introduction of Endonovo’s non-invasive bio-electrical medical devices to hospitals and clinics
• The global wearable medical devices market is expected to grow to nearly $67 billion by 2026 at a CAGR of 26.1 percent
• Endonovo holds 27 patents and numerous trademarks for several proprietary technologies and medical devices

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of non-invasive electroceutical therapeutic devices, has appointed Dr. Steven Levin, M.D., a national leader in the field of pain management, to its scientific advisory board. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. He is also an assistant professor at Johns Hopkins School of Medicine’s Department of Anesthesiology.

“Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,” Alan Collier, CEO of Endonovo Therapeutics, said in a news release (http://ibn.fm/UFbNO). “As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.”

Levin’s membership in professional and scientific societies has included the American Society of Anesthesiology, the American Pain Society, the American Society of Regional Anesthesia, the Society in Anesthesia and the International Association for the Study of Pain. He is currently the co-chair of the Opioid Stewardship Clinical Community, as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System.

“It is a great opportunity to participate in developing Endonovo’s promising fight to support pain management and healing in a natural and holistic way,” Levin stated in the release. “I look forward to helping guide Endonovo’s breakthrough treatments and fight against the opioid crisis as a member of the scientific advisory board.”

Levin will work with Endonovo to facilitate the introduction of SofPulse to health care facilities and further develop the company’s electroceutical devices pipeline. Endonovo has entered an agreement to distribute SofPulse to Veterans Administration facilities and Department of Defense health care facilities (http://ibn.fm/cc3ew), and the company recently announced its national rollout plan to be in hospitals throughout the nation by 2020 (http://ibn.fm/Us0G7).

SofPulse Electroceutical Therapy is a non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery (http://ibn.fm/V4CbG). SofPulse naturally speeds the healing process, significantly reduces pain and edema (swelling), reduces the need for addictive opioids and narcotics, and improves the patient recovery experience. Cleared by the FDA for treatment of post-surgical pain and swelling in the U.S., SofPulse is also CE-marked in Europe for the promotion of wound health and the palliative treatment of post-surgical pain and edema.

The National Institute on Drug Abuse reports that more than 130 people in the U.S. die each day after overdosing on opioids, while the Centers for Disease Control and Prevention estimates that the opioid crisis costs the nation a cumulative economic burden of more than $78 billion a year (http://ibn.fm/6UcfO).

The global wearable medical devices market is anticipated to grow to $66.8 billion by 2026, a Grandview Research report published in April 2019 suggests (http://ibn.fm/wd5AP). The market is forecast to expand at a CAGR of 26.1 percent over the period, with several factors contributing to the growth. Endonovo’s current portfolio of wearable medical products addresses conditions like liver disease, chronic kidney disease, cardiovascular and peripheral artery disease and ischemic stroke.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Nabis Holdings has closed on its previously announced initial purchase of a 49 percent interest in Cannova Medical Ltd., with an option to purchase the remaining 51 percent
• The company selected Cannova Medical for its unique approach to consumable cannabis technology and untapped industry potential
• Nabis sees Cannova as a potential disruptor in the edible cannabis industry

Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P), a leading Canadian investment company pursuing specialty investment opportunities in the burgeoning cannabis industry (among others), recently announced that it has now completed the purchase of a 49 percent interest in Cannova Medical Ltd., totaling 2,260,500 shares. Nabis retains the option to acquire the remaining 51 percent interest in Cannova.

Cannova Medical is a provider of innovative solutions for cannabis consumption. Pursuing its interest in investment across all vertically integrated aspects of the cannabis sector, with a focus on strategic revenue generation, Nabis selected Cannova because of its innovative take on consumable cannabis. In connection with this transaction, Nabis will have exclusive distribution rights in North America.

Cannova, based in Israel, is developing an alternative method for cannabis consumption in the form of a sublingual strip. The sublingual strips are infused with cannabis molecules that are produced using a patent-protected process involving the combination of various formulations with water soluble cannabinoids and natural active ingredients. The sublingual strip allows producers to more effectively control dosage quantities and significantly increases the effect of the cannabis, allowing it to be used for a variety of purposes, including pain management, as a concentration aid, as an antidepressant and to support better sleep.

Additionally, Cannova is developing the NovaJet Pro (“NovaJet”), an innovative printing machine that provides producers with the ability to create customized film strips, according to client demand, in real time. The NovaJet is expected to be able to assemble different quantities of cannabinoids and other natural substances, ultimately producing sublingual strips that are highly measured, accurate and tailored to specific demand.

Nabis CEO and Director Shay Shnet sees Cannova as a disruptor in the cannabis space as it relates to the way consumers view consumption (http://ibn.fm/OJlxj). “[Cannova’s] team has developed an innovative solution that largely appeals to consumers looking for convenience compared to current forms of consumption such as smoking, evaporation and ingestion of oil,” he said in a news release. “While we remain focused on our strategic plan for rapid expansion into limited-license states, we also pay close attention to companies that have the potential to disrupt the legal cannabis space. Cannova’s patent-protected solution allows the user to get a customized, personal combination of THC, CBD, and other active ingredients that meet[s] their personal, unique requirements in real time, thus changing the way cannabis is consumed.”

Shnet described Cannova’s product design as one that easily fits into the home of the average consumer, sitting on a countertop with a design akin to an average espresso or coffee machine while utilizing a “next-generation ability to combine various active ingredients.”

Looking to Nabis’s future with Cannova, Shnet spoke highly of the latter’s unique technology and its untapped industry potential. “We’re excited to team up with Nabis to provide cannabis users a safe, accurate and discrete way to consume cannabis,” he continued.

Cannova founder and CEO Omri Schanin indicated a promising future for Cannova with the assistance of Nabis. “The Nabis team, their experience and established network of cannabis-related portfolio, will help boost Cannova to become a cutting-edge leader in the space,” he added.

Utilizing Cannova’s innovative technology, Nabis is looking to disrupt the edibles sector and is well positioned to capitalize on the growing popularity of consumable cannabis.

For more information, visit the company’s website at www.NabisHoldings.com

NOTE TO INVESTORS: The latest news and updates relating to NABIF are available in the company’s newsroom at http://ibn.fm/NABIF

• TRXD sales grew to $1.5 million in Q1 2019; operating income also rose when compared to the same period of the prior year
• The company is adding new independent pharmacies and increasing pharmacy sales
• Mail-order pharmacy services and a newly launched mobile app offer lower prescription drug costs for U.S. consumers

Trxade Group Inc. (OTCQB: TRXD), an integrated pharmaceutical logistical services company that offers a web-based e-hub buying platform for transactions between independent pharmacists and drug manufacturers, reported record Q1 2019 revenues. The company also reported (http://ibn.fm/3NJq6) higher operating income, as it sees “continuing revenue growth and profitability in 2019.”

TRXD reported Q1 2019 sales of $1.5 million, as compared to $852,923 in revenues for the same period of the previous year. Operating income grew in Q1 2019 to $171,759 from $98,728 in Q1 2018. Net income reached $125,229 for Q1 2019, as compared to $82,269 for the same period of the previous year.

“Our 2019 fiscal year is off to a record start and in line with our primary objective of expanding our membership base while simultaneously focusing on increasing their utilization rates,” Trxade Group chairman and CEO Suren Ajjarapu stated in a news release. “At the end of the first quarter, we reported record platform subscribers and transactional revenue along with higher net and operating profits for the same period.”

TRXD’s proprietary trading platform enables independent pharmacies to buy online, directly from national pharmaceutical suppliers. The company attributed its revenue growth to an increase in its fee income from this web-based supplier-to-pharmacy trading platform, as well as increased pharmaceutical sales from its wholly owned subsidiary, Community Specialty Pharmacy LLC.

“Our proprietary software trading platform at www.Trxade.com, which enables independent pharmacies to purchase drugs, is adding new members on a monthly basis and, as a result, enabling us to experience strong top and bottom line growth across the board,” Ajjarapu added. In Q1 2019, TRXD added more than 400 new independent pharmacies, which were successfully onboarded on to the Trxade software trading platform.

On the consumer side, TRXD operates a full-service, mail-order business with pharmacy, warehouse and drug-delivery services, along with a mobile app – www.Delivmeds.com – that enables home delivery. These B2C offerings lower drug costs for U.S. consumers, the company said, and directly challenge the inefficient value chain by providing drug-price transparency and efficient buying and delivery of drugs.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Sproutly is a licensed producer with exclusive rights to Infusion Biosciences’ groundbreaking Aqueous Phytorecovery Process (“APP”) technology for naturally water-soluble cannabinoids
• Deloitte estimates that Canada’s cannabis edibles and topicals market could be worth $2.7 billion annually
• The company has entered into an exclusive joint venture with Moosehead Breweries Limited to develop and produce nonalcoholic, cannabis-infused beverages

Sproutly Canada Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) has reached another milestone by successfully completing the first run of the proprietary Aqueous Phytorecovery Process (“APP”) extraction technology licensed from Infusion Biosciences Inc., Sproutly CEO and Director Keith Dolo announced in a news release (http://ibn.fm/JJ0Yt).

“Sproutly has made significant progress towards building a world-class cannabis beverage and edibles company since going public in July of last year,” Dolo stated in the release. “The successful completion of our first run of the APP extraction technology in Canada marks a major milestone for our company and brings us another step forward in achieving our goal of becoming a leader in the cannabis infused product space.”

The initial APP run took place at Sproutly’s wholly owned Toronto Herbal Remedies Inc., an ACMPR-licensed facility designed and built for cultivating pharmaceutical-grade cannabis for the production and formulation of a natural, truly water-soluble cannabis solution. APP technology extracts water-soluble forms of cannabinoids (Infuz2O) and specific strains of oil-based cannabinoids (Bio Natural Oil), which were both successfully recovered during Sproutly’s first run of the proprietary technology.

“APP technology is a low-cost, gentle method to produce Infuz2O, a groundbreaking discovery that delivers the total effects of the strain of cannabis from which it is made; on-set effects start within approximately 5 minutes and dissipate within approximately 90 minutes,” Dolo stated in an earlier news release (http://ibn.fm/kFEBh).

Sproutly’s premium offering, Infuz2O, is described as “the world’s first and only truly water-soluble cannabis solution” for formulation into beverages. The Infuz2O water-soluble cannabinoids recovered during this first APP run are slated for product formulation and shelf-stability testing for fast-onset cannabis beverages under an exclusive joint venture with OCC Holdings Ltd., an affiliate of Moosehead Breweries Limited (http://ibn.fm/95xol). APP technology is also used in the production of Bio Natural Oils, which deliver the full-spectrum of cannabinoids and terpenes of the strain from which they are made, thus empowering consumers to enjoy the experience of their strains of choice in an edible form (http://ibn.fm/8i8QP).

Deloitte estimates that Canada’s cannabis edibles and beverages sectors will bring $2.7 billion per year into a market that is expected to generate higher profits for retailers (http://ibn.fm/8jRwC). Deloitte’s report, titled ‘Nurturing new growth: Canada gets ready for Cannabis 2.0’, indicates that the new legislation will likely attract consumers who have been reluctant to try traditional cannabis consumption methods.

Sproutly’s team is working diligently, developing and formulating fast-acting and long-lasting Infuz2O and Bio Natural Oil edible products for the Canadian market that meet Health Canada’s specialized regulations. A review of the final regulations for cannabis edibles, extracts and topical products, published on Lexology.com (http://ibn.fm/KLiOb), stated that, while the rules come into force on October 17, 2019, it will likely take until mid-December before consumers find the products on store shelves.

For more information, visit the company’s website at www.Sproutly.ca

NOTE TO INVESTORS: The latest news and updates relating to SRUTF are available in the company’s newsroom at http://ibn.fm/SRUTF

• The new version of the DehydraTECH delivery platform is suitable for use in pills, capsules and tablets for the pharmaceutical, medical and supplement markets
• DehydraTECH has demonstrated that it can deliver eight times more CBD into the blood than standard industry formulations
• Animal testing shows that combining DehydraTECH with a nanoemulsion formulation greatly assists delivery of cannabinoids and nicotine across the blood-brain barrier

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) new enhanced version of its patented delivery technology, DehydraTECH, has demonstrated that it can deliver eight-times more CBD into the blood and 19-times more CBD into the brain tissue than standard industry formulations. These results were confirmed in clinical lab tests conducted with live animals. LXRP has filed new patent applications based on these innovations (http://ibn.fm/5y9TR).

The new DehydraTECH delivery platform is ideally suited for solid-oral dosage forms such as capsules, pills and tablets for use by the pharmaceutical, medical and supplement markets.

LXRP intends to perform more studies on the enhanced DehydraTECH and focus on optimizing implementation regarding product applications for its licensees.

In earlier test results, LXRP announced that original or standard DehydraTECH combined with generic nanotech techniques delivers 1,137 percent more cannabidiol (CBD) into animal brain tissue following oral ingestion than certain existing industry formulations (http://ibn.fm/kxoTG). The tests consisted of oral administration of CBD into 10 male Sprague-Dawley rats.

In animal tests conducted in 2018 and 2019, results showed that DehydraTECH greatly assisted in the delivery of drugs, including nicotine and cannabinoids, across the blood-brain barrier. The demonstrated effectiveness of DehydraTECH, combined with nanoemulsification, significantly expands the application of the technology for conventional dosage forms, consumable liquids and beverage dosage forms.

LXRP is a Canadian bioscience company and a drug-delivery platform innovator. The company out-licenses its disruptive delivery technology, DehydraTECH. The technology is designed to promote healthier ingestion methods and lower overall dosing. Lexaria is the only company globally to have a patent issued for the oral delivery of all cannabinoids. DehydraTECH has received patents in the United States and Australia, and has multiple patents pending in more than 40 countries worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• Organigram is in a sharp growth pattern as the company builds toward its production capacity target of 113,000 kilograms of cannabis per year at its New Brunswick campus
• The company’s recent announcement of Health Canada’s licensing approval for an additional 17 cultivation rooms brings total licensed target production capacity to 61,000 kg per year
• The company announced a shipment of product to Quebec in June, marking its official fulfillment of an order to the last of Canada’s 10 provinces and establishment of its coast-to-coast network
• Organigram is also refurbishing its Moncton Campus for its own edibles facility and additional in-house extraction capacity

According to its announcement on June 24, Organigram Holdings Inc. (NASDAQ: OGI) (TSX.V: OGI) received licensing approval for 17 cultivation rooms to complete licensing of the Phase 4A development of its Moncton Campus in New Brunswick (http://ibn.fm/VGwBX) for total licensed target production capacity of 61,000 kg per year. By the end of the year, Organigram is expected to complete construction on Phase 4 expansion for total target production capacity of 113,000 kilograms per year, once fully licensed and operational⁽¹⁾.

The company is also refurbishing part of its facility at its Moncton Campus in order to pursue Phase 5 development of a cannabis edibles and derivatives facility and additional extraction capacity. The company has committed to invest C$15 million in a chocolate production line, with capacity of up to four million kilograms of chocolate cannabis edibles per year (http://ibn.fm/U7RNg).

Organigram began trading common shares on the Nasdaq in late May, uplisting from the OTCQX Best Market. One of only a handful of licensed producers operating in all of Canada’s provinces, the company celebrated the first shipment of its cannabis products to Quebec in June, marking official fulfillment of orders in all 10 provinces from coast to coast.

“Our national reach means brands such as Edison Cannabis Co. and Trailblazer are available across the country, offering a range of cannabis options for legal adult recreational cannabis consumers,” CEO Greg Engel stated in the news release announcing the shipment (http://ibn.fm/MRw2L). “As we look ahead to the legalization of edibles and extracts, we are excited to have the national network in place to offer Canadians access to new thinking and new products as they explore Cannabis 2.0, and a new cannabis experience.”

The company continues to build strategic partnerships as part of its focus on expanding globally, targeting international cannabidiol (CBD) product markets beyond Canada’s borders. In line with its strategy, the company generated positive adjusted EBITDA of C$13.3 million⁽²⁾ in the second quarter of its fiscal year, marking positive adjusted EBITDA for the third consecutive quarter.

For more information, visit the company’s website at www.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

(1) Several factors can cause actual capacity to differ. Please see the company’s latest MD&A and Annual Information Form.

(2) Adjusted EBITDA is a non-IFRS measure. Please see the company’s latest MD&A.

• Siyata Mobile offers the world’s first and only dedicated in-vehicle, 4G/LTE-capable smartphone specifically designed to optimize mobile communications while driving
• The company’s focus is on what three financial analysts suggest is a $13 billion total addressable market in North America, with no direct competition
• Siyata’s UV350 is the first in-vehicle mounted phablet approved for use on both the AT&T and FirstNet networks

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF), a leading global developer and provider of 3G and 4G/LTE in-vehicle smartphone cellular solutions, is making a major claim – development of the world’s 4G/LTE vehicle-mounted cellular device specifically designed for first responder and commercial fleet vehicles. Siyata Mobile is the only cellular vendor with a dedicated in-vehicle device – the Uniden UV350 – targeting this unique market segment in North America, which company research suggests is a more than $13 billion market (http://ibn.fm/pE0eE).

On a broader scale, the global LTE market is projected by Allied Market Research to reach $997 billion by 2020, growing at a compound annual growth rate of 58.2 percent from the forecast period of 2013-2020 (http://ibn.fm/9pxIQ). The report specifically identifies first responders as a sector seeking to adopt the more robust and high-speed communication service provided by 4G/LTE devices.

Siyata Mobile’s FirstNet Ready Uniden UV350 4G/LTE In-Vehicle Device for Public Safety (http://ibn.fm/U9fpc) is designed for the cabin of fire trucks, ambulances and police squad cars, combining the functions of multiple devices into one. It supports the FirstNet band 14 spectrum and gives public safety subscribers access to the dedicated, physically separate FirstNet network core that provides priority during emergencies.

With an estimated 10 million commercial trucks on America’s roadways and more than 3.5 million emergency vehicles responding to public safety needs, that’s a market segment Siyata Mobile is prepared to serve, said CEO and Chairman Marc Seelenfreund said in an interview with InvestorIntel (http://ibn.fm/V6p9Z).

“We have created a new category within the cellular device community. We are the first company to have developed vehicle mounted phablet, dedicated for the needs of commercial vehicles. It is a device that gives the ultimate communication for commercial vehicles,” Seelenfreund stated in the interview. The UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a large CAPEX, monthly fee and limited network coverage.

For more information, visit the company’s website at www.SiyataMobile.com

NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at http://ibn.fm/SYATF

• Golden Developing Solutions recently released its updated financial results, reporting 160 percent growth across multiple segments
• DNA Brands signed a preliminary agreement to enter the CBD marketplace with Golden Developing Solutions
• The company’s CBD Infusionz and Where’s Weed segments have been showing strong sales growth

Golden Developing Solutions Inc. (OTC: DVLP), an emerging leader in both the ancillary software and cannabidiol (CBD) products marketplace, recently released updated financial data highlighting tremendous growth for the company as a result of several strategic implementations.

Because of its expanded production capacity and the acquisition of Infusionz LLC, Golden Developing Solutions totaled more than $629,000 in monthly sales during May, boasting an annualized sequential monthly sales growth rate of almost 160 percent (http://ibn.fm/ZzCAu). Upon completion of its CBD Infusionz acquisitions, Golden Developing Solutions noted markedly accelerated growth across all segments.

Company CEO Stavros Triant shared his excitement for the company’s advantageous market position and its upcoming growth potential. “Everything is clicking right now. CBD Infusionz has moved into its expanded facility, and the booming demand continues” he said in a news release. “Our Where’s Weed segment is powering ahead at the same time. We couldn’t be more excited about how we are positioned right now and what we see ahead of us in coming months and quarters.”

Sales increases came from several of the company’s powerhouse players. Its Where’s Weed segment, an online and mobile cannabis-services hub, contributed most significantly by booking $135,000 in April sales and $153,000 in sales during May. This translates to 164 percent annualized sequential monthly sales growth. Additionally, CBD Infusionz demonstrated exceptional annualized sequential monthly growth of 158 percent, taking in $421,000 in April sales and $476,000 in May.

To add to its impressive financial performance, Golden Developing Solutions is pursuing a strategic partnership to broaden its industry presence. The company recently signed a preliminary partnership agreement with DNA Brands Inc. aimed at working together to reformulate the latter’s award-winning energy drink line to include CBD and natural sweeteners.

DNA Brands’ line of carbonated energy drinks and energy coffees includes a variety of flavors. The partnership agreement will allow Golden Developing Solutions to work with the DNA scientific team to reformulate, market and distribute the award-winning line of beverages. As part of the agreement, Global Developing Solutions has agreed to bear all costs associated with reformulation, production, packaging, advertising and distribution upon completion of a licensing deal.

“We will be working with our scientific team over at Parkside Beverage with the intent of reformulating and producing CBD-infused and non-CBD energy drinks,” DNA Brands CEO Adrian McKenzie stated in a news release (http://ibn.fm/dc7xS). “Licensing our proprietary brand of energy drinks to Golden Developing Solutions makes sense, in that it would provide us a platform to penetrate an extremely robust CBD market.”

For more information, visit the company’s website at www.GoldenDeveloping.com

NOTE TO INVESTORS: The latest news and updates relating to DVLP are available in the company’s newsroom at http://ibn.fm/DVLP

• SinglePoint emphasizes new technologies as it specializes in acquiring small to mid-sized businesses
• The company just announced a major premium hemp-flower contract
• SinglePoint is optimistic regarding the cannabis industry, bitcoin and blockchain technologies

SinglePoint Inc. (OTCQB: SING) is a technology and investment company based in Phoenix, Arizona. The company’s focus is on acquiring small to mid-sized firms that will benefit from the injection of growth capital and technology integration.

SinglePoint has a varied portfolio of undervalued subsidiaries with numerous revenue streams. The company’s visionary leadership team has wide-ranging experience in technology, engineering, marketing and raising capital.

SinglePoint diversifies into horizontal markets. The company researches opportunities where it can be active within an organization and influence strategy and direction. These target firms are typically undervalued and cash-flow positive, with high potential and verified assets (http://ibn.fm/4YHaH). SinglePoint has operations in diverse industries and verticals, including payment processing, cannabis, blockchain technologies and a crypto application co-created with AppSwarm (OTC: SWRM).

SinglePoint recently announced its entry into a multimillion-dollar contract with Elite Foundation LLC of North Carolina (http://ibn.fm/tJxxy). The contract is for the supply of more than 275,000 pounds of premium hemp flower over a period of 15 months. Elite Foundation adds value to hemp-centric businesses in the Southeast, providing ‘The Highest Grade’ of curated biological materials, agricultural expertise and consulting solutions to support sustainable growth.

Elite Foundation recently approved and took receipt of the second batch of product. In addition, Elite approved roughly 5,000 pounds of varietal-strain hemp flower. This has been reserved for its next four to six shipments, which are expected to occur every other week.

“This has been a great development for SinglePoint and our VP of Sales, Don Smith, has done a wonderful job of closing this contract,” SinglePoint President Wil Ralston stated in a news release. “He is currently working with additional clients in need of hemp flower as well as many other raw materials, such a biomass. We look forward to the closure of these deals among others in our pipeline including private-labeled finished goods for retail distribution. We see a large opportunity to put end-user product throughout retail distribution in the coming months.”

Of the contract, Elite Foundation chairman and CFO Max Alexander added, “We are grateful for the opportunity to work with SinglePoint in continuing to establish ourselves as the Southeast’s preferred hemp provider, trusted to satisfy our clientele’s growing demands by ensuring quality, consistency and variety for the downline.”

SinglePoint continues to diversify. The company acquired ShieldSaver in March 2018, expanding blockchain technology development into the automotive industry. SinglePoint’s pioneering bitcoin payment solution is poised to be a game changer for currently “unbankable” marijuana businesses (http://ibn.fm/fM4j1). Additionally, SinglePoint subsidiary SingleSeed launched a new retail website for CBD-based products in April 2018 (http://ibn.fm/gIjkA).

In addition, SinglePoint recently acquired Direct Solar. Since completion of the acquisition, Direct Solar has secured more than $400,000 in solar-installation contracts. Direct Solar is currently averaging 2.7 sales per day and has been trending toward three. The company is looking to expand into Missouri, as well (http://ibn.fm/bASZt).

Furthermore, SinglePoint recently announced a letter of intent to acquire ProActive Nutra. ProActive is a GMP- and FDA-compliant CBD, mushroom and herbal-cleanser manufacturing company. It has established a large following for its products, specifically the STAT! line of products, for which it currently has exclusive global distribution rights (http://ibn.fm/Fd43v).

SinglePoint continues to focus on its acquisition-based strategy. The company provides investors the opportunity to make investments across a broad range of assets. SinglePoint’s diversification mergers-and-acquisitions model offers a platform for sustainable growth and expansion into important markets.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Petroteq Energy is using its proprietary technology to revolutionize the domestic oil and gas industry through a “clean” closed-loop system that extracts fuel from sands and returns the cleaned sands to the earth
• Petroteq’s CEO narrates a new video tour of the company’s Utah extraction facility to explain the technology’s processes and its potential

Oil and gas industry technology developer Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is putting its revolutionary heavy oil recovery process on display with a seven-minute video tour of its facilities in Utah’s eastern desert to showcase what the company expects to be the best thing for domestic fuel production since fracking provided U.S. markets with a lower-cost alternative to conventional drilling operations.

The ‘Follow the Molecule’ video invites those interested in Petroteq’s closed-loop, environmentally “clean” surface oil extraction technology to consider the simplicity of the company’s flagship strategy for processing bituminous asphalt sands, turning the contaminated soil into “a clean dirt,” as PQEFF CEO David Sealock describes it (http://ibn.fm/R25eh).

“I am delighted to be able to show our investors the results of the company’s efforts over the last two years. We believe we have achieved commercial operations, both in terms of plant run time and quality of the crude oil produced,” Sealock stated in a news release (http://ibn.fm/xKzxt).

Petroteq’s current maintenance program will address key processes in the facility that have affected its operations, necessitating an amended production capacity timeline. However, when the maintenance program is completed, Petroteq intends to begin working toward phase 2 production rates of up to 4,000 barrels per day by the end of next year.

“These proactive equipment alterations are expected to decrease future maintenance costs and increase the efficiency of the facility in reaching its production goals, and is expected to ensure that the continued results of technology-driven efficiency improvements in the facilities performance meets the quality and high standards expected by the Company and its customers,” as Petroteq noted in a news release.

Petroteq has a total gross contingent resource of more than 130.5 million barrels of surface oil sands heavy oil in place at its Asphalt Ridge location. The company is contemplating a lease for two additional nearby sites, and an evaluation of contingent resources prepared by Chapman Petroleum Engineering Ltd. at the end of last year predicts that one of the new proposed leases contains gross contingent resources of 90 million barrels of mineable bitumen in place, with a net “arithmetic average after risk” estimate of 40.77 million barrels of mineable bitumen in place, while the other contains an estimated gross contingent of 41.3 million barrels of bitumen in place, with a net “arithmetic average after risk” estimate of 20.7 million barrels of bitumen in place.

While the company is focused on developing its oil sands resources and expanding production capacity at Asphalt Ridge, technology licensing opportunities are being reviewed to further the technological advancements that will benefit the industry.

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF